Etiopathogenetic mechanisms of fibromyalgia syndrome;Meccanismi eziopatogenetici della sindrome fibromialgica

Reumatismo

Volumn 60, Issue SUPPL. 1, 2007, Pages 25-35

  Stisi, S ^a   Cazzola, M ^b   Buskila, D ^c   Spath, M ^d   Giamberardino, M A ^e   Sarzi Puttini, Piercarlo ^f   Arioli, G ^g   Alciati, A ^f   Leardini, G ^h   Gorla, R ⁱ   Marsico, A ^j   Ceccherelli, F ^k   Bazzichi, L ^l   Carignola, R ^m   Gracely, R H ⁿ   Salaffi, F ^o   Marinangeli, F ^p   Torta, R ^m   Di Franco, M ^q   Biasi, G ^r   Cassisi, G ^s   Casale, R ^t   Altomonte, L ^u   Atzeni, F ^f   more..

^a G RUMMO HOSPITAL   (Italy)

^b Unit of Rehabilitative Medicine 'Hospital of Circolo'   (Italy)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF CHIETI   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g General Hospital of Pieve di Coriano (Mantua)   (Italy)

^h SS Giovanni e Paolo Hospital   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j Hospital of Taranto   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l UNIVERSITY OF PISA   (Italy)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^o UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^p UNIVERSITY OF L'AQUILA   (Italy)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r UNIVERSITY OF SIENA   (Italy)

^s Rheumatology Branch   (Italy)

^t IRCCS   (Italy)

^u S EUGENIO HOSPITAL   (Italy)

more..

Author keywords

Alterazioni del sistema nervoso; Alterazioni neuroendocrine; Autonomic nervous system.Parole chiave Sensibilizzazione centrale; Central sensitization; Fattori genetici; Genetic factors; Neuroendocrine abnormalities

Indexed keywords

ARTICLE; AUTONOMIC NERVOUS SYSTEM; ENDOCRINE DISEASE; FIBROMYALGIA; GENETICS; HUMAN; NERVOUS SYSTEM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM; ENDOCRINE SYSTEM DISEASES; FIBROMYALGIA; HUMANS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES;

EID: 69249235454     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2008.1s.25     Document Type: Article

References (106)

1. Sarnoch H, Adler F, Scholz OB. Relevance of muscular sensitivity, muscular activity, and cognitive variables for pain reduction associated with EMG feedback in fibromyalgia. Percept Mot Skills 1997; 84: 1043-50.
2. Jacobsen S, Petersen IS, Danneskiold-Samsoe B. Clinical features in patients with chronic muscle pain with special reference to fibromyalgia. Scand J Rheumatol 1993; 22: 69-76.
3. Kajantie E. Fetal origins of stress-related adult disease. Ann NY Acad Sci 2006; 1083: 11-27.
4. Phillips DI and Jones A. Fetal programming of autonomic and HPA function: do people who were small babies have enhanced stress response? J Phisiol 2006; 572: 45-50.
5. McBeth J, Morris S, Benjamin S, Silman AJ, Macfarlane GJ. Associations between adverse events in childhood and chronic widespread pain in adulthood: are they explained by differential recall? J Rheumatol 2001; 28: 2305-9.
6. Imbierowicz K, Egle UT. Childhood adversities in patients with fibromyalgia and somatoform pain disorder. Eur J Pain 2003; 7: 113-9.
7. Crofford LJ. Violence, stress, and somatic syndromes. Trauma Violence Abuse 2007; 8: 299-313.
8. Ablin JN, Shoenfeld Y, Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmun 2006; 27: 145-52.
9. Goldenberg DL: Do infections trigger fibromyalgia? (editorial). Arthritis Rheum 1993; 36: 1489-92.
10. Cruz BA, Catalan-Soares B, Proietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol 2006; 33: 2300-3.
11. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975; 47: 341-51.
12. Lavigne G, Brousseau M, Kato T Mayer P, Manzini C, Guitard F, et al. Experimental pain perception remains equally active over all sleep stages. Pain 2004; 110: 646-55.
13. Burckhardt CS, Clark SR, Campbell SM, O'Reilly CA and Bennett RM. Events and comorbidities associated with the onset of fibromyalgia. J Musculoskel Pain 1995; 3: 71.
14. Kosek E and Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain 2000; 4: 229-38.
15. McBeth J and Silman AJ. The role of psychiatric disorders in fibromyalgia. Curr Rheumatol Reports 2001; 3: 157-64.
16. Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. Am J Med 1998; 105: 74S-82S.
17. Vasey FB, Zarabadi SA, Seleznick M, Ricca L. Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol 2003; 2092-4.
18. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, Clauw DJ. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127: 835-43.
19. Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep 2007; 11: 333-8.
20. Hazlett DJ, Haines SN. Fibromyalgia: a time series analysis of the stressor-physical symptom association. J Behav Med 1992; 15: 541-8.
21. Kosek E, Fibromyalgia. In: F Cervero and TS Jensen (Eds), Handbook of Clinical Neurology, Vol 81 (3rd series), Elsevier, Edinburgh, London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto, 2006; 763-77.
22. Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain Headache Rep 2005; 9: 313-5.
23. Buskila D, Neumann L, Press J. Genetic factors in neuromuscular pain. CNS Spectr 2005; 10: 281-4.
24. Buskila D, Sarzi Puttini P. Genetic aspects of fibromyalgia syndrome. Arthr Res Ther 2006; 8: 218-25.
25. Clauw DJ, Crofford LJ. Chronic widewspread pain and fibromyalgia, what we know and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 685-701.
26. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996; 26: 605-11.
27. Buskila D, Neumann L. Fibromyalgia Syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 1997; 24: 941-4.
28. Arnold LM, Hudson J, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum 2004; 50: 944-52.
29. Offenbaecher M, Bondy B, de Jong S, Glalzender K, Kruger M, Schoeps P, Ackenheil M. Possible association of fibromyalgia with a polymorphism in the regulatory region. Arthritis Rheum 1999; 42: 2482-8.
30. Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, et al. The T 102 C polymorphism of the 5-HT2A receptor gene in fibromyalgia. Neurobiol Dis 1999; 6: 433-39.
31. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism and relationship to anxiety related personality traits. Arthritis Rheum 2002; 46: 845-7.
32. Zubieta JK, Heitzeg M, Smith YR. COMT Val 158 Met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299; 5610: 1240-3.
33. Gursoy S, Erdal E, Herken H, Ma denci E, Ala B, Erdal N. Significance of catechol-O-methyl-transferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003; 23: 104-7.
34. Vargas-Alarcon G, Fragosos JM, Gruz-Robeles D, Vergas A, Lao-Villadoniga JI, Garcia-Fructuoso F. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007; 9: R110.
35. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to personality traits. Mol Psychiatry 2004; 9: 730-1.
36. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846-50.
37. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91: 165-75.
38. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain 1999; 79: 75-82.
39. Schadrack J, Zieglgänsberger W. Activity-dependent changes in the pain matrix. Scand J Rheumatol 2000; 113: 19-23.
40. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 1998; 25: 152-5.
41. Zieglgansberger W, Herz A. Changes of cutaneous receptive fields of spino-cervical-tract neurones and other dorsal horn neurones by microelectrophoretically administered amino acids. Experimental Brain Research 1971; 13: 111-26.
42. Davies SN, Lodge D. Evidence for involvement of Nmethylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat. Brain Res 1987; 424: 402-6.
43. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995; 75: 193-200.
44. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987; 26: 1235-8.
45. Staud R, Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med 2001; 2: 208-15.
46. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev 2004; 27: 729-37.
47. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997; 70: 41-51.
48. Kranzler JD, Gendreau JF, Rao SG. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 2002; 36: 165-213.
49. Mense S. Neurobiological concepts of fibromyalgia-the possible role of descending spinal tracts. Scand J Rheumatol 2000; 29: 24-9.
50. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007; 27: 10000-6.
51. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, Clauw DJ. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127: 835-43.
52. Hrycaj P, Stratz T, Muller W. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1993; 20: 1986-8.
53. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19: 90-4.
54. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986; 81: 85-9.
55. Russell IJ. Neurochemical pathogenesis of fibromyalgia. Z Rheumatol 1998; 57: 63-6.
56. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989; 19: 158-63.
57. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/ fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 35: 550-6.
58. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 2001; 40: 290-6.
59. Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain 2000; 14: 37-46.
60. Murphy RM, Zemlan FP. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berl) 1987; 93: 118-21.
61. Bradley LA, Alberts KR, Alarcon GS. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum [abstract] 1996; 39: 212.
62. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593-601.
63. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-6.
64. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease inmetenkephalin-ARG-PHE levels in CSF from fibromyalgia patients. J Musculoske Pain 1995; 3: 4.
65. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998; 315: 377-84.
66. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988; 33: 3-9.
67. Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic fluid in patients with chronic pain. Semin Arthritis Rheum 1998; 27: 348-59.
68. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg 1988; 67: 976-81.
69. Tsigos C, Diemel LT, White A, Tomlinson DR, Young RJ. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci (Lond) 1993; 84: 305-11.
70. Schwarz MJ, Späth M, Müller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neuroscience Letters 1999; 259: 196-8.
71. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999; 26: 1564-9.
72. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003; 48: 2916-22.
73. Muller W, Schneider EM, Stratz T. The classification of fibromyalgia syndrome. Rheumatol Int 2007; 27: 1005-10.
74. Turk DC, Okifuji A, Sinclair JD, Starz TW. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 1996; 23: 1255-62.
75. Stisi S, Venditti C, Sarracco I, Prevalenza di stressors percepiti in pazienti con fibromialgia primaria. Progressi in Reumatologia Clinica 2007; 1 (Suppl. 1): 67.
76. Dessein PH, Shipton EA, Stanwix AE, Joffe BI. Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm. Pain 2000; 86:213-5.
77. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system and fibromyalgia, Arthritis Res Ther 2007; 9: 216-25.
78. Riedel W, Schlapp U, Leck S, Netter P, Neeck G. Blunted ACTH and cortisol responses to systemic injection of corticotropine-releasing hormone (CRH) in fibromyalgia. Ann NY Acad Sci 2002; 966: 483-90.
79. Tsigos C, Chrousos GP. Hypothalamic-pituitaryadrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865-71.
80. Wingenfeld K, Wagner D, Schmidt I, Meinlschmidt G, Hellhammer DH, Hein C. The low-dose dexam ethasone suppression test in fibromyalgia. J Psychosom Res 2007; 62: 85-91.
81. Crofford LJ. Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci 1998; 315: 359-66.
82. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007; 10: 13-25.
83. Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased Neural sympathetic activation in fibromyalgia syndrome. Ann NY Acad Sci 2006; 1069: 109-17.
84. McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006; 31: 2776-82.
85. Lariviere WR, Melzack R. The role of corticotrophinreleasing factor in pain and analgesia. Pain 2000; 84: 1-14.
86. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative Review: The Pathophysiology of Fibromyalgia. Ann Int Med 2007; 146: 726-34.
87. Neeck G. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992; 19: 1120-2.
88. Korszun A, Young EA, Engleberg NC, Masterson L, Dawson EC, Spindler K, et al. Follicular phase hypothalamic pituitary-gonadal axis function in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 2000; 27: 1526-30.
89. Samborski W, Sobieska M, Pieta P, Drews K, Brzosko M. Normal profile of sex hormones in women with primary fibromyalgia. Ann Acad Med Stetin 2005; 51: 23-6.
90. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007; 36: 357-79.
91. Panerai A, Vecchiet J, Panzeri P, Meroni PL, Scarone S, Pizzigallo E, et al. Peripheral Blood Mononuclear Cell [beta]-Endorphin Concentration Is Decreased in Chronic Fatigue Syndrome and Fibromyalgia but Not in Depression: Preliminary report. Clin J Pain 2002; 18: 270-3.
92. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/ fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 5: 550-6.
93. Giovengo S, Russell I, Larson A. Increased concentration of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999; 26: 1564-9.
94. Russell IJ. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin N Am 2002; 28: 329-42.
95. Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004; 62: 420-4.
96. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003; 75: 77-82.
97. Buskila D, Press J. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue. Best Pract Res Clin Rheumatol 2001; 15: 747-75.
98. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system and fibromyalgia, Arthritis Res Ther 2007; 9: 216.
99. Vaeroy H, Qiao Z-G, Morkrid L, Forre O. Altered sympathetic nervous system response in patients with fibromyalgia (Fibrositis syndrome). J Rheumatol 1989; 16: 1460-5.
100. Cohen H, Neumann L, Kotler M, Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. IMAJ 2001; 3: 755-60.
101. Kooh M, Martinez-Lvin M, Meza S, Martin-del-Campo A, Hermosillo AG, Pineda C, Nava A, Amigo MC, Drucker-Colin R. Concurrent heart rate variability and polysomnography analyses in fibromyalgia patients. Clin Exp Rheumatol 2003; 21: 529-30.
102. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, Porta A, et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 2005; 32: 1787-93.
103. Anderberg UM, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia syndrome patients. Eur J Pain 1999; 3: 19-30.
104. Wallace D, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001; 40: 743-9.
105. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative Review: The Pathophysiology of Fibromyalgia. Ann Int Med 2007; 146: 726-34.
106. Van Houdenhovea B, Egle U.T.-Fibromyalgia: a stress disorder? Psychother Psychosom 2004; 73: 267-75.